Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates


INVO Bioscience

  ( )

vista's key points

  • INVO is commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective & affordable treatment for patients diagnosed with infertility.
  • INVOcell addresses key industry challenges regarding cost & capacity constraints: ability to help treat underserved patients as an alternative to traditional in vitro- fertilization (IVF)
  • ~$15-$18 Billion global infertility industry growing ~8-10% annually.
  • Vast underserved global market ~95%+ of infertile individuals go untreated: significant unmet market opportunity.
  • U.S. commercialization agreement in January 2019 with Ferring Pharmaceuticals a multi-national firm and significant player in the global fertility drug market.
  • Distribution agreements in eight countries located within Africa, Asia, Europe and the Middle East.
  • Seeking to establish the initial 1-2 JV agreements, in Q1, for INVO-only clinics within the U.S. market.

company profile


vista's view

INVO Bioscience successfully conducted a public offering in November 2020, raising net proceeds of approximately $11.6 million at $3.20/share while uplisting the company onto the NASDAQ market. These moves strengthened their balance sheet & their position to execute on their commercialization efforts in the US and around the world. Analysts...

Read More

Page View Count : 97863

exclusive content


Vista Partners creates exclusive content based on the ongoing research of companies included in the VP Watchlist.

vp watchlist

The VP Watchlist contains current coverage companies that deserve consideration for short term and long term portfolio additions.